Over the last decade we have witnessed an avalanche of newly identified risk factors for
venous thrombosis. This has advanced our knowledge of its etiology, because more …

BACKGROUND:: Oral contraceptives were introduced in the late 1950s, and their use has
altered society and has led to radical changes. Combined oral contraceptives are …

Background: A reduced sensitivity for activated protein C (APC) is associated with an
increased risk of venous thrombosis even in the absence of the factor (F) V Leiden mutation …

The purpose of this study was to examine patterns of use for oral contraceptive and
desmopressin acetate nasal spray, both used in managing menorrhagia in adolescents with …

We determined anticoagulant parameters that depend on protein S function in plasma, ie the
APC-independent anticoagulant activity of protein S (expressed as pSR) and APC …

Oral contraceptive (OC) use increases venous thrombosis (VTE) risk and causes activated
protein C (APC) resistance. Plasma glucosylceramide (GlcCer) deficiency is associated with …

Oral estrogen treatment increases thrombotic risk. Tissue factor (TF), tissue factor pathway
inhibitor (TFPI), and platelet interaction with leukocytes are important determinants of …

Hormonální antikoncepci užívá více než 100 miliónů žen po celém světě. Přesto, že dnes
jsou užívána kontraceptiva s nízkým obsahem estrogenů, riziko žilního tromboembolizmu …

Background: A reduced sensitivity for activated protein C (APC) is associated with an
increased risk of venous thrombosis even in the absence of the factor (F) V Leiden mutation …

Protein S (PS), a cofactor of activated protein C (APC), is a vitamin Kldependent
anticoagulant plasma protein, which is produced mainly in the liver but which is also …